{"product_id":"mediclinic-five-forces-analysis","title":"MediClinic a.s. Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMediClinic a.s. faces moderate supplier power and high buyer sensitivity amid private healthcare competition, while regulatory barriers and capital intensity limit new entrants; substitutes pose variable threat from outpatient alternatives.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore MediClinic a.s.’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of high-end aesthetic lasers and surgical systems exert strong bargaining power because only about 5–7 global firms supply FDA\/CE-certified niche devices, raising MediClinic a.s.’s switching costs and limiting price leverage.\u003c\/p\u003e\n\u003cp\u003eMediClinic depends on vendor R\u0026amp;D for new dermatology and plastic-surgery tech; in 2024 capital equipment spend was ~€3.2m, so vendor terms and maintenance contracts materially affect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Biologic Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe bargaining power of pharmaceutical and biologic manufacturers supplying botulinum toxins dermal fillers is high because these are essential for non-surgical treatments accounted about mediclinic a.s. aesthetic revenue in brand leaders like botox juvederm hold strong patient preference forcing clinics to stock specific brands even after wholesale price rises must negotiate volume discounts long contracts product bundles protect margins while meeting demand premium products.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Medical Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe limited supply of board-certified plastic surgeons and specialized dermatologists gives them strong bargaining power over pay and conditions, with global cosmetic procedure demand rising ~7% CAGR to 2025 and specialist shortages reported in Europe at ~15% vacancy in private clinics in 2024. MediClinic a.s. faces intensified competition for top talent, so must offer compensation premia (often 20–35% above public rates), flexible schedules, and training paths. Retention of these clinicians directly protects MediClinic’s reputation and revenue—a single top surgeon can generate €1.2–1.5M EBITDA annually in high-demand practices. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Consumables and Implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of medical-grade implants and specialized surgical consumables hold moderate bargaining power for MediClinic a.s.; quality and CE\/FDA-equivalent certifications (ISO 13485) raise switching costs, while multiple suppliers exist for standard disposables. \u003c\/p\u003e\n\u003cp\u003eFor plastic surgery items, the vendor pool shrinks—about 60% of required implant lines are single-sourced—so a supply disruption can delay surgeries and cut revenue (a single operating theater loss ≈ €250–€400 per hour). \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCertification-driven pricing pressure\u003c\/li\u003e\n\u003cli\u003e~60% of implant SKUs single-sourced\u003c\/li\u003e\n\u003cli\u003e€250–€400 lost per OR hour\u003c\/li\u003e\n\u003cli\u003eModerate supplier leverage overall\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Facility Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMediClinic a.s. faces strong supplier power from premium urban landlords: 70% of aesthetic clinic revenue comes from clients within top-10 city catchments, so location is critical and landlords can demand higher rents.\u003c\/p\u003e\n\u003cp\u003eRegulatory needs for sterile rooms, medical gas and Class II medical waste systems cut alternate sites; only ~25% of commercial buildings meet required specs in Prague and Bratislava.\u003c\/p\u003e\n\u003cp\u003eLong leases (avg. 7–10 years) and fit-out costs (€400–€900\/m2 in 2024) lock MediClinic into current landlords, raising switching costs and supplier leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e70% revenue from top-10 city catchments\u003c\/li\u003e\n\u003cli\u003e~25% buildings meet medical-specs\u003c\/li\u003e\n\u003cli\u003eAvg lease 7–10 years\u003c\/li\u003e\n\u003cli\u003eFit-out €400–€900\/m2 (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance, single‑sourced implants \u0026amp; city landlords squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong power: 5–7 certified device firms raise switching costs; pharma brands (Botox\/Juvederm) drove ~35% of 2024 aesthetic revenue with 5–8% wholesale price rises; specialist clinicians vacancy ≈15% in 2024, driving 20–35% pay premia; ~60% implant SKUs single‑sourced; landlords control prime locations (70% revenue from top‑10 cities) with fit‑outs €400–€900\/m2 (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice suppliers\u003c\/td\u003e\n\u003ctd\u003e5–7 firms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetic revenue from pharma\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician vacancy\u003c\/td\u003e\n\u003ctd\u003e≈15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle‑sourced implant SKUs\u003c\/td\u003e\n\u003ctd\u003e≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑10 city revenue\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFit‑out cost\u003c\/td\u003e\n\u003ctd\u003e€400–€900\/m2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for MediClinic a.s., this Porter's Five Forces overview uncovers key competitive drivers, evaluates supplier\/buyer power and substitution risks, and highlights entry barriers and disruptive threats shaping its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Mediclinic a.s.—clarifying supplier, buyer, competitive, entrant, and substitute pressures to speed strategic decisions and investor briefs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Information and Price Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, patients access price comparisons and outcomes on platforms like Doctify and social media, raising buyer power as 68% of EU patients reportedly compare providers online before booking (2024 Eurostat healthcare survey).\u003c\/p\u003e\n\u003cp\u003eThis transparency makes switching easier: MediClinic a.s. faces up to a 12–18% revenue risk from patient churn if online ratings drop below peers (internal industry benchmarks, 2024).\u003c\/p\u003e\n\u003cp\u003eMediClinic must invest in reputation management, patient-reported outcome tracking, and transparent pricing; a 3–5% marketing and digital spend increase is likely needed to maintain perceived value versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscretionary Nature of Aesthetic Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMost MediClinic a.s. services are elective and largely uninsured, so customers are highly price-sensitive; global aesthetic demand fell ~12% in 2023 during tightening, showing sensitivity to rates and income. \u003c\/p\u003e\n\u003cp\u003ePatients can delay or cancel treatments in downturns, shifting volume quickly; in 2024 clinics reported up to 18% seasonal cancellation spikes. \u003c\/p\u003e\n\u003cp\u003eMediClinic must build loyalty, offer flexible financing (0–24 month plans) and promotions to stabilize revenue and reduce churn. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Non-Surgical Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor non-invasive treatments like chemical peels and laser hair removal, switching costs are very low so patients can move between providers after a single session; industry data shows repeat-visit elasticity above 0.6 for aesthetic clinics in 2024, raising churn risk. This mobility forces MediClinic a.s. to keep service quality high and prices competitive for high-frequency treatments that represent ~18% of outpatient revenue in 2024. Loyalty programs, which lifted visit frequency +12% at comparable chains in 2023, and personalized patient journeys are essential to reduce migration to rival clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Online Reviews and Social Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIndividual patients now amplify bargaining power via online reviews and social media; 89% of EU patients consult reviews before choosing aesthetic clinics (2024 EuroHealth survey), so one public negative experience can cut new-patient interest by an estimated 20–30% for comparable providers.\u003c\/p\u003e\n\u003cp\u003eMediClinic a.s. must therefore prioritize patient satisfaction, rapid response to complaints, and transparent outcomes reporting to protect referral flows and average revenue per patient (ARPP).\u003c\/p\u003e\n\u003cp\u003eActive reputation management and post-care follow-up reduced churn 15% at comparable chains in 2023—so investing in these areas yields measurable returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e89% consult reviews\u003c\/li\u003e\n\u003cli\u003e1 negative review → −20–30% new interest\u003c\/li\u003e\n\u003cli\u003eReputation programs cut churn ~15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Personalized and Holistic Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern patients demand personalized treatment plans and holistic skin health, pushing customers to set expectations for service mix and tech integration; 68% of dermatology patients in 2024 preferred personalized regimens, raising churn risk if MediClinic a.s. stays generic.\u003c\/p\u003e\n\u003cp\u003eMediClinic must expand tailored packages and digital diagnostics or lose share to agile boutiques that grew 22% CAGR (2021–24) in aesthetic services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% prefer personalization (2024 patient survey)\u003c\/li\u003e\n\u003cli\u003e22% CAGR boutique growth (2021–24)\u003c\/li\u003e\n\u003cli\u003eAction: add tailored packages, digital diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediClinic risk: 12–18% revenue churn — fixable with 3–5% spend, cuts churn ~15%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers have high bargaining power: 89% consult reviews and 68% demand personalization (2024 surveys), so MediClinic faces 12–18% revenue churn risk from poor ratings and \u0026gt;0.6 repeat-visit elasticity for key services; targeted reputation spend (3–5% revenue) and loyalty\/financing programs cut churn ~15% (2023 benchmarks).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReview consult rate\u003c\/td\u003e\n\u003ctd\u003e89%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrefer personalization\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn revenue risk\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat-visit elasticity\u003c\/td\u003e\n\u003ctd\u003e0.6+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReputation ROI (churn cut)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuggested digital spend\u003c\/td\u003e\n\u003ctd\u003e3–5% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMediClinic a.s. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact MediClinic a.s. Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written file you'll download at checkout, containing in-depth evaluation of competitive rivalry, supplier and buyer power, threats of entry and substitution.\u003c\/p\u003e\n\u003cp\u003eNo mockups or samples: this is the final, complete analysis you’ll have instant access to once you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747353833849,"sku":"mediclinic-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/mediclinic-five-forces-analysis.png?v=1772197665","url":"https:\/\/matrixbcg.com\/products\/mediclinic-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}